Insider trading

Period: 120 months Stock: MDGL Minimum amount: $10M × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

18 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

18 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

18 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

18 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
18 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
18 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

18 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
9 Jan 2026
FRIEDMAN PAUL A Director
Sold on a plan 29×
$12.96M 24,800 at 522.71
11.7%
Planned (10b5-1)
10 Dec 2025
FRIEDMAN PAUL A Director
Sold on a plan 9×
$13.69M 24,800 at 552.18
11.7%
Planned (10b5-1)
10 Dec 2025
Taub Rebecca Director
Sold on a plan 9×
$10.30M 18,650 at 552.15
3.9%
Planned (10b5-1)
20 Aug 2025
BAKER BROS. ADVISORS LP Director · indirect
Bought 22×
$23.07M 59,901 at 385.16
3.2%
18 Aug 2025
BAKER BROS. ADVISORS LP Director · indirect
Bought 32×
$38.85M 105,782 at 367.26
5.9%
Largest buy in 3 yrs
13 Aug 2025
FRIEDMAN PAUL A Director
Sold on a plan 17×
$47.83M 129,172 at 370.24
40.8%
Planned (10b5-1)
12 Aug 2025
FRIEDMAN PAUL A Director
Sold on a plan 10×
$15.51M 43,605 at 355.68
18.9%
Planned (10b5-1)
12 Aug 2025
Taub Rebecca Director
Sold on a plan 10×
$15.39M 43,263 at 355.69
8.6%
Planned (10b5-1)
13 Dec 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 16×
$17.81M 81,159 at 219.39
4.8%
Largest buy in 3 yrs
21 Nov 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 20×
$12.13M 64,350 at 188.47
4.0%
Largest buy in 3 yrs
14 Nov 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 14×
$11.15M 71,848 at 155.15
4.9%
Largest buy in 3 yrs
13 Nov 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 18×
$10.00M 69,839 at 143.21
5.0%
First buy on file
13 Dec 2019
CRAVES FRED B Director · indirect
Sold, plan not stated 2×
$126.56M 1,200,000 at 105.47
93.2%
Sold half or more
13 Dec 2019
BAY CITY CAPITAL LLC 10% owner · indirect
Sold, plan not stated 2×
$126.56M 1,200,000 at 105.47
93.2%
Sold half or more
11 Jun 2018
BAY CITY CAPITAL LLC Director · indirect
Sold, plan not stated 2×
$80.49M 280,000 at 287.46
71.2%
Sold half or more
11 Jun 2018
CRAVES FRED B Director · indirect
Sold, plan not stated
$78.79M 274,092 at 287.46
4.9%
11 Jun 2018
Taub Rebecca Chief Medical Officer, EVP R&D · indirect
Bought
$21.14M 73,526 at 287.46
12.6%
First buy on file
11 Jun 2018
FRIEDMAN PAUL A Chief Executive Officer · indirect
Sold, plan not stated
$21.14M 73,526 at 287.46
10.1%
Showing 1–18 of 18.